Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Public ClinicalTrials.gov record NCT04030559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects
Study identification
- NCT ID
- NCT04030559
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of California, Davis
- Other
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- ATM Gene Mutation
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- BRIP1 Gene Mutation
- CDK12 Gene Mutation
- CHEK1 Gene Mutation
- CHEK2 Gene Mutation
- DNA Damage Response Gene Mutation
- DNA Repair Gene Mutation
- FANCA Gene Mutation
- FANCD2 Gene Mutation
- FANCL Gene Mutation
- GEN1 Gene Mutation
- NBN Gene Mutation
- Prostate Carcinoma
- RAD51 Gene Mutation
- RAD51C Gene Mutation
Interventions
- Niraparib Drug
- Niraparib Tosylate Monohydrate Drug
- Radical Prostatectomy Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 24, 2020
- Primary completion
- Jan 9, 2024
- Completion
- Nov 6, 2025
- Last update posted
- May 13, 2026
2020 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04030559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04030559 live on ClinicalTrials.gov.